Although over 40 million people benefit every year from the use of medical isotopes, innovation in the field has been restricted in the identification and manufacturing of appropriate radioisotopes. Worldwide shortages have regularly plagued the industry. Serva’s competitive advantage resides in the company’s suite of proprietary technologies which not only allow for the identification of new and better pathways to develop the currently used radioisotopes, but also hold promise for identifying and developing new medical radioisotopes. With technology that allows for the identification of all possible pathways to develop all medical isotopes, Serva is poised to be a significant disrupter in the industry and catalyst for groundbreaking biomedical research.
During the Med Tech Accelerator, Serva and Mayo faculty identified Ac-225 as a critical radioisotope in the treatment of cancer. In the few weeks following, Serva identified a novel pathway to create Ac-225, ran preliminary experiments, and began exploring opportunities to collaborate in the production of this critical isotope. Through the combined efforts of Serva and Mayo Clinic, the time from problem identification to isotope development shrunk from months or years to just a few weeks.
"The network that we gained access to through the program at Mayo Clinic, ASU and the greater Phoenix Biotech ecosystem has been a game changer for Serva, accelerating the growth of the medical sector of our company."
Sarah Jones, PhD
Vice President, Serva Medical